NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-22-208 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-22-010 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to establish a Data Analysis and Coordination Center (DACC) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Disease Study Sites (RFA-HG-22-008) and the Omics Production Center(s) (RFA-HG-22-009), the DACC will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. The DACC will be primarily responsible for coordinating Consortium logistics, outreach, and dissemination of findings; for managing and securing Consortium data; for creating the multi-dimensional dataset; and for coordinating and contributing to consortium-wide protocol development, data analysis, and methods development efforts. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.
Funding Opportunity RFA-HG-22-009 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to establish Omics Production Center(s) (OPC(s)) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Disease Study Sites (RFA-HG-22-008) and the Data Analysis and Coordination Center (RFA-HG-22-010), the Omics Production Center(s) will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. The OPC(s) will be primarily responsible for using high high-throughput molecular assays to produce omics data from the biosamples provided by the Disease Study Sites (DSS, RFA-HG-22-008) and contributing to consortium-wide protocol development, data analysis, methods development, and the production of the multi-dimensional dataset. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.
Notice NOT-DK-22-029 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-22-008 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to establish Disease Study Sites (DSS) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Omics Production Centers (RFA-HG-22-009) and the Data Analysis and Coordination Center (RFA-HG-22-010), the Disease Study Sites will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. Each DSS will be primarily responsible for proposing a study focused on a disease area for which integrative multi-omics could be used to define associations with healthy and disease states and to detect changes over time. Each DSS will utilize effective strategies to enroll and consent participants, collect phenotypic and environmental exposure data, collect samples and measures over time, and contribute to consortium-wide protocol development, data analysis, methods development, and the production of the multi-dimensional dataset. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.
Notice NOT-GM-22-045 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-202 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-125 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-23-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to form Transporter Elucidation Centers (TECs) as part of a Transporter Elucidation Network (TEN). TECs funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will address key knowledge gaps in functional transport of nutrients and drugs to the developing fetus and infant through a focus on human placenta, lactating mammary gland, and developing gut. Such projects may necessitate deorphanization and characterization of understudied transporters and functional variants. The NICHD-funded TECs will work together to generate knowledge and resources that will be shared with the broader research community to advance our understanding of nutrient, drug, and supplement transport to the developing fetus and infant.
Notice NOT-HD-22-042 from the NIH Guide for Grants and Contracts
Notice NOT-EY-22-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-22-020 from the NIH Guide for Grants and Contracts. The purpose of this fundng opportunity announcemnt (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.
Notice NOT-AR-23-005 from the NIH Guide for Grants and Contracts
Notice NOT-DA-22-079 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) awardees from underrepresented groups (URGs), while promoting scientific advancements through diversification of NCIs investigator pool. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply.
Funding Opportunity PAR-22-233 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support research to understand health outcomes related to an unexpected and/or time-sensitive event (e.g., emergent environmental threat; pandemic; change in local, state, or national policy; natural disaster). Applications in response to this FOA must demonstrate that the research proposed is time-sensitive and must be initiated with minimum delay due to a limited window of opportunity to collect baseline data, answer key research questions, and/or prospectively evaluate a new policy or program. This FOA is intended to support opportunities in which empirical study could only be available through expedited review and funding, necessitating a substantially shorter process than the typical NIH grant review/award cycle. The time from submission to award is expected to occur within 4-5 months. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.
Funding Opportunity PAR-22-202 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.
Funding Opportunity PAR-22-200 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline.
Funding Opportunity RFA-AG-23-018 from the NIH Guide for Grants and Contracts. This RFA supports a national survey of professional dementia care providers and link consented survey respondents (providers and institutional representative) that consent to administrative data (e.g., electronic health records, claims, payroll, other institutional and state level data). This new resource anticipates the integration from administrative sources with the provider survey to expand research on the dementia care workforce, supply of skilled labor, and provide deeper insight into how professional care providers and institutions provide care for persons living with dementia. The national survey will oversample individuals from populations underrepresented in research on Alzheimers disease and related dementias (AD/ADRD) who serve in various professional caregiving roles (e.g., physicians, other care providers such as licensed practical nurses [LPNs], social workers) and institutions serving predominately underrepresented populations. This will allow examination of how the characteristics of professional care providers and the institutions employing them lead to variation in care provided to persons living with dementia and identify modifiable organization and individual behaviors that can improve overall health care delivery and eliminate AD/ADRD disparities.
Notice NOT-HL-22-048 from the NIH Guide for Grants and Contracts